| 1 |
Hage K, Boyd A, Davidovich U, Zantkuijl P, Hoornenborg E, Matser A, Generaal E, Schinkel J, Todesco E, van der Valk M, Rougier H, Lacombe K, Prins M; ICECREAM study group. Evaluating interventions to reduce behaviour associated with HCV reinfection in men who have sex with men: study protocol for a non-blinded, phase 2, randomised trial. Trials 2023;24:193. [PMID: 36922871 DOI: 10.1186/s13063-023-07161-y] [Reference Citation Analysis]
|
| 2 |
Hage K, Boyd A, Davidovich U, Zantkuijl P, Hoornenborg E, Matser A, Generaal E, Schinkel J, Todesco E, Valk MVD, Hayette R, Lacombe K, Prins M. Evaluating interventions to reduce behaviour associated with HCV reinfection in men who have sex with men: study protocol for a non-blinded, phase 2, randomised trial.. [DOI: 10.21203/rs.3.rs-2374681/v1] [Reference Citation Analysis]
|
| 3 |
Brothers S, DiDomizio E, Nichols L, Brooks R, Villanueva M. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. AIDS Behav 2023;27:119-33. [PMID: 35776253 DOI: 10.1007/s10461-022-03749-8] [Reference Citation Analysis]
|
| 4 |
van Santen DK, Sacks-Davis R, Stewart A, Boyd A, Young J, van der Valk M, Smit C, Rauch A, Braun DL, Jarrin I, Berenguer J, Lazarus JV, Lacombe K, Requena MB, Wittkop L, Leleux O, Salmon D, Bonnet F, Matthews G, Doyle JS, Spelman T, Klein MB, Prins M, Asselin J, Stoové MA, Hellard M; InCHEHC study group. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019. EClinicalMedicine 2023;56:101810. [PMID: 36618902 DOI: 10.1016/j.eclinm.2022.101810] [Reference Citation Analysis]
|
| 5 |
De La Espriella Palmett VM, Urán JM, Orrego M, Navas MC. Reinfección por virus de la hepatitis C: revisión de tema y presentación de un caso. Rev colomb Gastroenterol 2022;37:434-443. [DOI: 10.22516/25007440.917] [Reference Citation Analysis]
|
| 6 |
Factor SH, Fierer DS. Can treatment, without prevention, eliminate hepatitis C among men who have sex with men? J Viral Hepat 2022;29:1048-9. [PMID: 35748744 DOI: 10.1111/jvh.13726] [Reference Citation Analysis]
|
| 7 |
Raya RP, Curtis H, Kulasegaram R, Cooke GS, Burns F, Chadwick D, Sabin CA; BHIVA Audit and Standards Sub-committee. The British HIV Association national clinical audit 2021: Management of HIV and hepatitis C coinfection. HIV Med 2022. [PMID: 36172948 DOI: 10.1111/hiv.13417] [Reference Citation Analysis]
|
| 8 |
Popping S, Cuypers L, Claassen MAA, van den Berk GE, De Weggheleire A, Arends JE, Boerekamps A, Molenkamp R, Koopmans MPG, Verbon A, Boucher CAB, Rijnders B, van de Vijver DAMC. Persistent Transmission of HCV among Men Who Have Sex with Men despite Widespread Screening and Treatment with Direct-Acting Antivirals. Viruses 2022;14:1953. [PMID: 36146760 DOI: 10.3390/v14091953] [Reference Citation Analysis]
|
| 9 |
Prinsenberg T, Schinkel J, Zantkuijl P, Davidovich U, Prins M, van der Valk M. Internet-guided HCV-RNA testing: A promising tool to achieve hepatitis C micro-elimination among men who have sex with men. J Viral Hepat 2022;29:677-84. [PMID: 35583928 DOI: 10.1111/jvh.13706] [Reference Citation Analysis]
|
| 10 |
Garvey L, Cooke GS. Engaging with HCV reinfection to advance microelimination. Lancet HIV 2022;9:e372-4. [PMID: 35659331 DOI: 10.1016/S2352-3018(22)00128-X] [Reference Citation Analysis]
|
| 11 |
Isfordink CJ, Smit C, Boyd A, de Regt MJA, Rijnders BJA, van Crevel R, Ackens RP, Reiss P, Arends JE, van der Valk M; ATHENA observational cohort. Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands. AIDS 2022;36:773-83. [PMID: 34999607 DOI: 10.1097/QAD.0000000000003159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Johannesson JM, Fridriksdottir RH, Löve TJ, Runarsdottir V, Hansdóttir I, Löve A, Thordardottir M, Hernandez UB, Olafsson S, Gottfredsson M; TraP Hep C group. HIGH RATE OF HCV REINFECTION AMONG RECENTLY INJECTING DRUG USERS: RESULTS FROM THE TRAP HEP C PROGRAM - A PROSPECTIVE NATIONWIDE, POPULATION-BASED STUDY. Clin Infect Dis 2022:ciac272. [PMID: 35438144 DOI: 10.1093/cid/ciac272] [Reference Citation Analysis]
|
| 13 |
Kusejko K, Salazar-Vizcaya L, Shah C, Stöckle M, Béguelin C, Schmid P, Ongaro M, Darling K, Bernasconi E, Rauch A, Kouyos RD, Günthard HF, Böni J, Fehr JS, Braun DL; Swiss HIV Cohort Study. Sustained effect on hepatitis C elimination among men who have sex with men in the Swiss HIV Cohort Study: A systematic re-screening for hepatitis C RNA two years following a nation-wide elimination program. Clin Infect Dis 2022:ciac273. [PMID: 35404384 DOI: 10.1093/cid/ciac273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Prinsenberg T, Illidge J, Zantkuijl P, Bedert M, Prins M, van der Valk M, Davidovich U. Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study. PLoS One 2022;17:e0263654. [PMID: 35180246 DOI: 10.1371/journal.pone.0263654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Téllez MJ, Domínguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero-Román A, Santos I, Giner L, Armiñanzas C, Montero M, Manzardo C, Cifuentes C, García C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodríguez C, Gaspar G, Pérez L, Losa JE, Force L, Veloso S, Martínez-Alfaro E, Jarrín I, De Miguel M, González Garcia J; GeSIDA 8514 Study Group. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. HIV Med 2022. [PMID: 35037379 DOI: 10.1111/hiv.13229] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 16 |
Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 66] [Article Influence: 53.0] [Reference Citation Analysis]
|
| 17 |
van Dijk M, Brakenhoff SM, Isfordink CJ, Cheng WH, Blokzijl H, Boland G, Dofferhoff ASM, van Hoek B, van Nieuwkoop C, Sonneveld MJ, van der Valk M, Drenth JPH, de Knegt RJ. The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. J Clin Med 2021;10:4562. [PMID: 34640576 DOI: 10.3390/jcm10194562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 18 |
Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Sandmann L, Deppe J, Beier C, Ohlendorf V, Schneider J, Wedemeyer H, Wedegärtner F, Cornberg M, Maasoumy B. Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience. Open Forum Infect Dis 2021;8:ofab325. [PMID: 34377724 DOI: 10.1093/ofid/ofab325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 20 |
Mukherjee S, Colby D, Ramautarsing R, Popping S, Sriplienchan S, Chinbunchorn T, Phanuphak N, van de Vijver D. Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: A cost effectiveness modelling study. J Virus Erad 2021;7:100042. [PMID: 34141441 DOI: 10.1016/j.jve.2021.100042] [Reference Citation Analysis]
|
| 21 |
Martínez-Rebollar M, De La Mora L, Campistol M, Cabrera B, Bagué A, De Lazzari E, Torres B, González-Cordón A, Inciarte A, Ambrosioni J, Martínez E, Blanco JL, Forns X, Blanch J, Mallolas J, Laguno M. Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study. Infect Dis Ther 2021;10:1253-66. [PMID: 33914265 DOI: 10.1007/s40121-021-00448-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
